132873-77-9

Basic information

• Product Name: 1H-Benzimidazole-1-carboxylic acid, 4-(bromomethyl)-, 1,1-dimethylethyl ester
• CAS NO: 132873-77-9
• Molecular Formula: C13H15BrN2O2
• Molecular Weight: 311.178
• Mol File: 132873-77-9.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: 1H-Benzimidazole-1-carboxylic acid, 4-(bromomethyl)-, 1,1-dimethylethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Benzimidazole-1-carboxylic acid, 4-(bromomethyl)-, 1,1-dimethylethyl ester(132873-77-9)
• EPA Substance Registry System: 1H-Benzimidazole-1-carboxylic acid, 4-(bromomethyl)-, 1,1-dimethylethyl ester(132873-77-9)

Safety Data

• Hazardous Substances Data: 132873-77-9(Hazardous Substances Data)

Usage

General Description

1H-Benzimidazole-1-carboxylic acid, 4-(bromomethyl)-, 1,1-dimethylethyl ester is a chemical compound with the molecular formula C13H16BrN3O2. 1H-Benzimidazole-1-carboxylic acid, 4-(bromomethyl)-, 1,1-dimethylethyl ester is a derivative of benzimidazole and is commonly used in organic synthesis and medicinal chemistry. It contains a bromomethyl group and a 1,1-dimethylethyl ester group, which are important for its reactivity and solubility. 1H-Benzimidazole-1-carboxylic acid, 4-(bromomethyl)-, 1,1-dimethylethyl ester has potential applications in the development of pharmaceuticals and other bioactive compounds due to its chemical structure and properties. Additionally, it may have uses in other industries such as agriculture and materials science.

Upstream product

• 65658-13-1 (1H-benzo[d]imidazol-4-yl)methanol 
• 1352721-36-8 tert-butyl 4-(hydroxymethyl)-1H-benzo[d]imidazole-1-carboxylate 
• 37619-25-3 methyl 1H-benzo[d]imidazole-4-carboxylate 
• 24424-99-5 di-tert-butyl dicarbonate 
• 139525-24-9 4-methylbenzimidazole-1-carboxylic acid,1,1-dimethylethyl ester 
• 132875-27-5 tert-butyl 4-(dibromomethyl)-1H-benzimidazole-1-carboxylate 
• 4887-83-6 4-methylbenzimidazole 

Downstream Products

• 1352874-02-2 N-{4'-[3-(1H-Benzoimidazol-4-ylmethyl)-6-fluoro-2-imino-2,3-dihydro-benzoimidazol-1-yl]-5-chloro-biphenyl-2-yl}-acetamide 

Relevant articles and documents

BENZOXAZINONE DERIVATIVES FOR THE TREATMENT OF GLYTL MEDIATED DISORDERS

The present invention relates to benzoxazinone derivatives, processes for their preparation, pharmaceutical compositions and medicaments containing them and to their use in treating disorders mediated by GlyT1, including neurological and neuropsychiatric disorders, in particular psychoses, dementia or attention deficit disorder.

PIPERIDINYL SUBSTITUTED 1,3-DIHYDRO-BENZOIMIDAZOL-2-YLIDENEAMINE DERIVATIVES

The invention relates to new derivatives of formula (I) wherein the substituents are as defined in the specification; to processes for the preparation of such derivatives; pharmaceutical compositions comprising such derivatives; such derivatives as a medicament; such derivatives for the treatment of one or more IGF-1R mediated disorders or diseases

Heterocyclic amines having central nervous system activity

Tricyclic nitrogen containing compounds, having central nervous system activity of the following structural formula: STR1 and pharmaceutically acceptable salts thereof wherein R1, R2, and R3 are independently hydrogen, C1-6 alkyl, alkenyl, or alkynyl, C3-10 cycloalkyl, or R1 and R2 are joined to form a C3-7 cyclic amine which can contain additional heteroatoms; X is hydrogen, C1-6 alkyl halogen, hydroxy, alkoxy, cyano, carboxamide, carboxyl, or carboalkoxyl; A is SO2, N, CH, CH2, CHCH3, C=O, C=S, C-SCH3, C=NH, C-NH2, C-NHCH3, C--NHCOOCH3, or C--NHCN. B is CH2, CH, C=O, N, NH or N--CH3 ; n is 0 or 1; and D is CH, CH2, C=O, O, N, NH or N--CH3. These new compounds are suitable for treating schizophrenia, Parkinson's disease, anxiety, depression or as compounds for lowering blood pressure in animal or human hosts.